Covid19: Clinical Trials

2,117 trials for Covid19, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1195 completed, 593 unknown, 153 terminated, 110 withdrawn. 491 Not applicable, 332 Phase 2, 233 Phase 3, 135 Phase 1, 67 Phase 4.

By phase and status

PhaseTrialsStatus
Not applicable491Completed 310, Unknown 122, Terminated 27, Withdrawn 20, Active not recruiting 7, Recruiting 3, Suspended 2
Phase 2332Completed 137, Unknown 81, Terminated 64, Withdrawn 37, Recruiting 5, Active not recruiting 3, Not yet recruiting 2, Suspended 2, Enrolling by invitation 1
Phase 3233Completed 111, Unknown 72, Terminated 25, Withdrawn 20, Suspended 3, Active not recruiting 2
Phase 1135Completed 74, Unknown 29, Terminated 15, Withdrawn 14, Recruiting 2, Not yet recruiting 1
Phase 467Completed 36, Unknown 21, Terminated 6, Withdrawn 4
Early Phase 111Completed 4, Withdrawn 3, Terminated 2, Active not recruiting 1, Unknown 1

Follow Covid19: new trials by email Literature Review of Covid19 trials Research Report on Covid19

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Perceptions of Undergraduate Students and Teaching Staff on Online Teaching
Questionnaire - Covid19
SuspendedMisr International University92092027-07-152026-10-08
Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS
AVM0703, Placebo - ARDS, Covid19
Phase 1Not yet recruitingAVM Biotechnology Inc162026-12-012025-10-02
Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 Acute Respiratory Distress Syndrome
Instilled T3, Placebo Therapy - Covid19, SARS-CoV Infection
Phase 2WithdrawnUniversity of Minnesota2026-01-152026-02-10
"Efesovir" (FS-1) for COVID-19, Phase 2
Efesovir - Covid19
Phase 2Not yet recruitingScientific Center for Anti-infectious Drugs, Kazakhstan622025-12-012024-04-17
Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix
COVID-19 Therapeutic Biologic Mix - NOVAVAX COVID-19 VACCINE plus BCG Vaccine Mix for percutaneous use - Covid19
Early Phase 1Active not recruitingHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair202025-05-182026-06-10
Respiratory Muscle Assesment in COVID-patients Without Hospitalization
Comprehensive assessment of respiratory muscle function. - Covid19, Diaphragm Injury
CompletedRWTH Aachen University252024-12-012026-01-28
The VIDA After COVID Study
Virtual Intervention Program - Covid19
Not applicableWithdrawnMayo Clinic2024-12-012025-03-25
ExoFlo™ Infusion for Post-Acute COVID-19 and Chronic Post-COVID-19 Syndrome
Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles, Saline - Covid19, Postviral Syndrome
Phase 1 / Phase 2WithdrawnDirect Biologics, LLC2024-11-012024-11-22
Clinical Study for Subjects With COVID-19 Using Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells
Allogeneic adipose-derived stem cells - Corona Virus Infection, Covid19
Phase 2Not yet recruitingCelltex Therapeutics Corporation302024-11-012024-02-07
A Safety Assessment of the iZephyr Hood for NIV in COVID-19 Patients
iZephyr hood - Aerosol Disease, Covid19
Not applicableUnknownImperial College Healthcare NHS Trust302024-06-012024-03-13
NAC for Attenuation of COVID-19 Symptomatology
N-acetylcysteine, Placebo - Covid19, COVID-19 Pneumonia
Phase 2UnknownCambridge Health Alliance2002024-03-312023-08-07
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise
COVI-MSC, Placebo - Covid19
Phase 2WithdrawnSorrento Therapeutics, Inc.2024-02-012024-04-17
Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation
Biopsy and Cytobrush - Covid19, Olfactory Dysfunction
Not applicableRecruitingUniversitaire Ziekenhuizen KU Leuven2402024-01-242026-05-06
Risks and Outcomes Among COVID-19 Patients Admitted to Assiut University Hospital.
Covid19
UnknownAssiut University2002023-12-202023-12-19
SLV213 Treatment in Ambulatory COVID-19 Patients
SLV213, Placebo - Covid19
Phase 2UnknownKenneth Krantz, MD, PhD812023-11-012023-04-12
COVID-19 ThromboprophylaXIs Study of Novel FXIa Inhibitor Frunexian (EP-7041) in ICU Patients
EP-7041 Injection - Thrombopenia, Covid19
Phase 2WithdrawneXIthera Pharmaceuticals2023-10-012023-10-05
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
Placebo, Metformin - Covid19
Phase 3CompletedSusanna Naggie, MD32142023-09-052025-11-18
The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19
MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8), MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8), MSC-exosomes delivered intravenously every other day (8:8:8) - Covid19, Novel Coronavirus Pneumonia
Phase 1 / Phase 2UnknownAVEM HealthCare552023-09-012022-03-11
Hyperbaric Oxygen Therapy for Post-COVID-19 Syndrome
Hyperbaric oxygen, Sham - Covid19, Neurocognitive Dysfunction
Not applicableRecruitingAssaf-Harofeh Medical Center912023-06-012026-04-21
Efficacy of Home Inspiratory Muscle Training in Post-covid-19 Patients: a Randomized Clinical Trial
Inspiratory muscle training - Covid19
Not applicableUnknownUniversidade Federal do Rio Grande do Norte102023-05-012023-05-10

Showing 20 of 2117. Sign in to see all of them.

Narrower conditions

COVID-19 (2117)  ·  Coronavirus Infections (178)  ·  Severe Acute Respiratory Syndrome (141)  ·  Respiratory Distress Syndrome (47)  ·  Pneumonia (42)  ·  Anxiety Disorders (38)  ·  Respiratory Insufficiency (35)  ·  Pneumonia, Viral (26)  ·  Virus Diseases (26)  ·  Post-Acute COVID-19 Syndrome (25)  ·  Depression (23)  ·  Neoplasms (23)  ·  Critical Illness (22)  ·  Motor Activity (22)  ·  Cytokine Release Syndrome (21)

Broader conditions

Respiratory Tract Diseases (2114)  ·  Coronaviridae Infections (2111)  ·  Nidovirales Infections (2111)  ·  Lung Diseases (2110)  ·  RNA Virus Infections (2108)  ·  Infections (2104)  ·  Respiratory Tract Infections (2104)  ·  Pneumonia, Viral (2091)  ·  Virus Diseases (2091)  ·  Pneumonia (2075)  ·  Coronavirus Infections (1939)  ·  Pathological Conditions, Signs and Symptoms (319)  ·  Pathologic Processes (222)  ·  Signs and Symptoms (118)  ·  Behavior (115)

Interventions

Standard of Care (49)  ·  Surveys and Questionnaires (42)  ·  Ivermectin (38)  ·  Blood Specimen Collection (34)  ·  Hydroxychloroquine (34)  ·  remdesivir (26)  ·  COVID-19 Vaccines (23)  ·  Azithromycin (19)  ·  Dexamethasone (16)  ·  Exercise (14)  ·  Vitamin D (13)  ·  Hematologic Tests (12)  ·  Sodium Chloride (12)  ·  favipiravir (12)  ·  nitazoxanide (12)

Sponsors

Assiut University (31)  ·  Assistance Publique - Hôpitaux de Paris (28)  ·  Mayo Clinic (14)  ·  Fondation Hôpital Saint-Joseph (13)  ·  Sorrento Therapeutics, Inc. (13)  ·  Stanford University (13)  ·  Ain Shams University (12)  ·  Cairo University (10)  ·  Centre Hospitalier Universitaire, Amiens (10)  ·  Hospices Civils de Lyon (10)  ·  Kanuni Sultan Suleyman Training and Research Hospital (10)  ·  Massachusetts General Hospital (10)  ·  University of Pennsylvania (10)  ·  Hacettepe University (9)  ·  The University of Hong Kong (9)

Countries

United States (463)  ·  France (195)  ·  Turkey (Türkiye) (125)  ·  Italy (107)  ·  United Kingdom (107)  ·  Spain (102)  ·  Egypt (90)  ·  Brazil (87)  ·  Canada (85)  ·  Belgium (60)  ·  Mexico (52)  ·  Germany (44)  ·  Argentina (34)  ·  China (32)  ·  Netherlands (31)

Top investigators

Mike Royal, MD (12)  ·  Adrian Hernandez, MD (8)  ·  Susanna Naggie, MD (8)  ·  Neha Sharma (5)  ·  Abhimanyu Kumar (4)  ·  Emad R Issak, MD (4)  ·  Neven Sarhan, PhD (4)  ·  Prof. James Neaton (4)  ·  Amina Asif, MPhilMicro (3)  ·  Andy Goren, MD (3)  ·  Flavio Cadegiani, MD (3)  ·  Hong Ren, PH D (3)  ·  Ivan Fan-ngai Hung (3)

Results publications

PMID 34473343, PMID 31986264, PMID 35244208, PMID 32031570, PMID 32109013, PMID 36695483, PMID 37489818, PMID 37591523, PMID 33757717, PMID 35713300, PMID 32007143, PMID 32091533, PMID 32112977, PMID 32142651, PMID 32159775, PMID 32167524, PMID 32171076, PMID 32211963, PMID 33502773, PMID 34658014, PMID 38597249, PMID 39272117, PMID 19887665, PMID 20160606, PMID 21435708, PMID 24693893, PMID 27344959, PMID 28802696, PMID 29680828, PMID 29757717, PMID 30566567, PMID 32064853, PMID 32066541, PMID 32083985, PMID 32101510, PMID 32113509, PMID 32150748, PMID 32155105, PMID 32172242, PMID 32187464, PMID 32203977, PMID 32251768, PMID 32311448, PMID 32325282, PMID 32350462, PMID 32396163, PMID 32399710, PMID 32504052, PMID 32555424, PMID 32907855

NIH funding

U24TR001608 (8), 1OT2HL156812-01 (3), 3UL1TR002538-03S2 (2), 1ZIDES102465 (1), 3UG1DA050066-02S1 (1), 3UL1TR003017-02S2 (1), 5U2CDK114886 (1), OT2HD107553-01 (1), P20GM104417 (1), P30AG024824 (1), P30AG034532 (1), P30AG064199 (1), P50CA244433 (1), P50HD103525 (1), R01AG056587 (1)